-+ 0.00%
-+ 0.00%
-+ 0.00%

Roche's GIP/GLP-1 dual receptor agonist enicepatide has successfully reached two major endpoints in its phase II clinical trial involving obesity and type 2 diabetes.

智通财经·09/22/2026 05:09:00
语音播报
Roche's GIP/GLP-1 dual receptor agonist enicepatide has successfully reached two major endpoints in its phase II clinical trial involving obesity and type 2 diabetes.